stockportfolio.pro
ARS Pharmaceuticals, Inc. (SPRY)
Healthcare · Biotechnology · NasdaqGM
ARS Pharmaceuticals, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $5.51M | $1.32M | $30,000 | $89.15M | $84.28M |
| Gross profit | — | — | — | $30,000 | $88.17M | $63.85M |
| Net income | $-32.95M | $-20.24M | $-34.68M | $-54.37M | $8.00M | $-171.30M |
| Net margin | — | -367.7% | -2635.4% | -181216.7% | 9.0% | -203.3% |
Source: ARS Pharmaceuticals, Inc. SEC filings (10-K).
Explore 6 years of ARS Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SPRY in your portfolio →
ARS Pharmaceuticals, Inc. financial history by metric
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
ARS Pharmaceuticals, Inc. — frequently asked questions
What is ARS Pharmaceuticals, Inc.'s revenue?
ARS Pharmaceuticals, Inc. (SPRY) reported revenue of $84.28M for fiscal year 2025, down 5.5% from the prior year, according to its SEC filings.
Is ARS Pharmaceuticals, Inc. profitable?
No — SPRY reported a net loss of $-171.30M in fiscal 2025.
What is SPRY's P/E ratio?
ARS Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does ARS Pharmaceuticals, Inc. have?
As of fiscal year 2025, SPRY carried roughly $96.37M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is ARS Pharmaceuticals, Inc.'s gross margin?
SPRY's gross margin was 75.8% in fiscal 2025 — gross profit of $63.85M on revenue of $84.28M.
What is ARS Pharmaceuticals, Inc.'s market cap?
ARS Pharmaceuticals, Inc. (SPRY) has a market capitalization of about $938.42M, based on the latest data in our nightly-refreshed cache.
When does ARS Pharmaceuticals, Inc.'s fiscal year end?
SPRY's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from ARS Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.